Here’s the version of predictive modelling in pharma that doesn’t get discussed enough in vendor conversations: the one where the model performs brilliantly in internal validation, gets deployed, and then produces predictions that don’t correspond to clinical reality. The analytics team is confused. The architecture was sound. The methodology was rigorous. And the problem, when someone finally investigates it carefully, turns out to be the training dataset — a claims-based patient cohort with systematic biases that the model learned and amplified rather than corrected for.
Outcome prediction models built on real-world data fail not because the modelling methodology is wrong but because the data specification was inadequate from the start. Feature completeness was assumed rather than verified. Outcome labelling quality was taken on trust rather than validated against clinical records. Data leakage risk wasn’t assessed before training began. And the validation framework — held-out test set from the same database, same time period, same coding environment — detected none of it.
This post covers what pharma data scientists, RWE Directors, and commercial analytics teams actually need to know before building predictive models on claims data: what makes a dataset suitable for model training, what rigorous validation looks like beyond internal cross-validation, and where synthetic data genuinely helps versus where it creates the kind of analytical risk that surfaces expensively at deployment. It connects to the broader data source landscape covered in the RWD Medical pillar page and builds on the phenotype validation methodology discussed in our post on phenotype validation in claims data — because outcome labelling quality for predictive models and phenotype algorithm quality for observational studies are, methodologically, the same problem.
The Three Primary Use Cases — and What Each Requires from the Data
Predictive modelling in pharma clusters around three primary applications. The mistake most teams make is treating these as variations on the same analytical problem. They’re not — each has distinct data requirements that need to be specified before any data source evaluation begins.
Patient Stratification
Patient stratification models identify which patients within a disease population are most likely to progress, respond to a specific treatment, experience adverse events, or transition to higher cost-of-care tiers. The commercial applications are significant — from targeting clinical trial recruitment to identifying patients most likely to benefit from a new therapy at launch. The data requirements are equally specific: sufficient longitudinal depth to observe patient trajectories over the relevant follow-up horizon, complete diagnostic coding across the full comorbidity profile, and population coverage broad enough to ensure the training cohort is representative of the target population rather than just the patients who present most frequently to high-coding institutions.
The most consistent failure mode in stratification model development is training on a dataset that over-represents high-utilisation patients — those with the most complete records — and under-represents patients who disengage from the healthcare system before reaching the outcome the model is designed to predict. The model learns to identify patients who look like high-utilisers, not patients who will actually experience the outcome. This is a dataset selection problem, not a modelling problem, and it can’t be fixed after the fact.
Treatment Response Prediction
Treatment response prediction models estimate the probability that a given patient will respond to a specific therapeutic intervention, based on baseline characteristics, prior treatment history, and real-world outcome patterns in similar patients. These models are increasingly used to support label expansion submissions, personalised medicine programmes, and market access negotiations where payer evidence requirements include subgroup response data.
This is the use case where the connection to phenotype algorithm quality is most direct and most consequential. A model trained on a poorly validated patient cohort produces response estimates that are statistically precise but clinically meaningless — they describe the behaviour of the algorithm’s misclassified cohort, not the actual patient population. The same rigour that applies to phenotype algorithm validation for observational studies applies to outcome labelling for treatment response model training. Sensitivity, specificity, and positive predictive value of the outcome algorithm set the upper bound on model performance — no architectural sophistication recovers from a 70% PPV outcome label.
Commercial Forecasting
Commercial forecasting models use real-world prescription data, treatment patterns, and market dynamics to project brand performance, estimate market share trajectories, and support launch planning and loss-of-exclusivity modelling. This is the use case where data recency matters most and longitudinal depth matters least — the predictive horizon is typically measured in quarters rather than years, and near-real-time prescription data with consistent geographic coverage across target markets is the primary data requirement.
Commercial forecasting is also where synthetic data augmentation has its most straightforward application. Scenario modelling for launch conditions, competitive entry events, and policy changes that haven’t yet occurred can be structured as synthetic data generation problems without the clinical validity constraints that apply to treatment response prediction — and this is where the analytical value of synthetic approaches is clearest and most defensible. More on the boundaries of that in the synthetic data section below.
What Makes a Claims Dataset Suitable for Predictive Model Training
The question “is this dataset suitable for predictive model training?” is more demanding than “is this dataset suitable for descriptive epidemiology?” Predictive models don’t just describe the data — they learn its patterns, including its biases, gaps, and systematic distortions. A dataset that produces acceptable descriptive statistics may produce a deeply flawed predictive model if its structural characteristics aren’t evaluated carefully before training begins.
Feature Completeness and Covariate Coverage
A predictive model is only as good as the features it can access. For claims-based models, that means evaluating whether the dataset captures the variables most predictive of the outcome of interest with sufficient completeness and accuracy. Claims data captures billing events reliably and clinical detail poorly. For many prediction tasks, important predictive features — disease severity, functional status, laboratory values, physician assessment — are either absent or proxied through indirect indicators that introduce noise.
Before committing to a claims dataset for model training, map the features your model architecture requires against what the dataset actually contains. For each important feature not directly available in claims, assess whether a credible proxy exists, what bias that proxy introduces, and whether that bias is directional — systematic enough to be corrected — or random noise that simply reduces model performance. This mapping exercise is the analytical equivalent of the data requirements specification framework we cover for longitudinal studies in our post on longitudinal data analysis in pharma — the principle is identical: specify requirements before evaluating sources, not the other way around.
Completeness analysis requires particular care in clinical datasets because missing values rarely occur randomly. A missing laboratory value may indicate a test was not performed — a clinically meaningful signal — or a result that was not recorded, which is an administrative artefact. These two scenarios require fundamentally different imputation approaches and affect model validity differently. Standard missing data analysis that treats both scenarios identically introduces systematic errors that compromise model generalisability across patient populations and care settings. Structured completeness assessment protocols that distinguish between clinically significant missingness and administrative gaps are a prerequisite for reliable clinical ML dataset preparation.
Outcome Definition and Labelling Quality
Supervised machine learning models require labelled outcomes — patients who experienced the event of interest, correctly identified and correctly timed. In claims data, outcome labelling quality depends directly on phenotype algorithm performance. A poorly validated outcome algorithm produces training labels that are systematically wrong, and a model trained on systematically wrong labels learns to predict the algorithm’s misclassification pattern rather than the clinical outcome.
This is the intersection between predictive modelling and phenotype validation that most teams underestimate. Sensitivity, specificity, and positive predictive value of the outcome algorithm determine the upper bound on model performance before a single training epoch begins. Validation of outcome labels against gold-standard clinical records — the same process described for patient cohort phenotyping — is not optional for models intended for regulatory or market access purposes.
AI-Readiness Beyond Standard Data Quality
A dataset that meets conventional data quality standards — complete, accessible, interoperable, reusable — is not necessarily AI-ready in the sense that matters for predictive model training. AI-ready clinical datasets require additional characteristics that standard quality frameworks don’t address: deep provenance tracking that enables complete lineage from original data collection through every transformation step; statistical validation of distribution characteristics that affect model performance across different patient populations; semantic consistency in how clinical concepts are coded across time periods and care settings; and pre-model explainability documentation that supports regulatory audit requirements.
Deep provenance is particularly important for pharma predictive modelling programmes that will ultimately support regulatory submissions or market access negotiations. A model whose training data cannot be traced back to its original source — with every transformation documented — will not survive regulatory scrutiny regardless of its predictive performance. Building provenance documentation into the data preparation process rather than attempting to reconstruct it after the fact is substantially more reliable and substantially less expensive. This connects directly to the data provenance requirements covered in the context of longitudinal dataset specification in our post on longitudinal data analysis in pharma.
Temporal Structure and Data Leakage Prevention
Data leakage — the inadvertent inclusion of future information in model training features — is one of the most common and most consequential errors in predictive modelling with longitudinal healthcare data. It’s also one of the most reliably undetected errors in internal validation, because a leaked model performs well on any held-out set from the same data source where the leakage is present.
Preventing data leakage requires explicit specification of the prediction horizon and the feature observation window before model training begins. Every feature included in the model must be verifiably observable at the time of prediction — which in claims data means accounting for data latency, coding lag, and the time between clinical events and their appearance in the claims record. A model that performs well in internal validation and dramatically worse in deployment is a data leakage problem until proven otherwise.
Population Representativeness and Bias Detection
The population in the training dataset needs to be representative of the population the model will be applied to in deployment. Insurance-based patient cohorts systematically over-represent insured populations, high-utilisation patients, and patients treated at institutions with high claims completeness. For Pan-European applications, this means evaluating representativeness across national markets rather than assuming that a dataset with broad coverage in one market generalises to others. Coding practices, treatment patterns, and healthcare utilisation vary enough across Continental European markets that a model trained on data from one market may require retraining or recalibration before deployment in another. The vendor evaluation framework we’ve developed covers how to assess geographic representativeness claims from data providers specifically.
Beyond geographic variation, non-randomised clinical data sources introduce selection biases that require explicit detection before model training begins. Claims-based datasets exhibit systematic biases related to insurance coverage type, healthcare access patterns, and diagnostic coding practices that vary across payer environments. A model trained without identifying these biases learns them as signal — and then reproduces them in deployment, performing well in populations that resemble the training data and poorly in those that don’t.
Bias detection requires comparative analysis across demographic groups, geographic regions, and healthcare systems to identify systematic differences in data collection, coding practices, and patient representation. Variable quality evaluation should also examine data entry patterns that create artificial correlations — default value insertion, copy-paste errors in EHR workflows, and systematic under-coding in specific care settings are common sources of dataset-level bias that are invisible in aggregate quality statistics but material to model performance. These analyses need to be completed and documented before model training begins, not discovered during external validation.
Validating Models Trained on Claims Data Against Clinical Outcomes
Model validation is where most pharma predictive modelling programmes reveal their weaknesses. Internal validation — splitting the training dataset into training and test sets and evaluating performance on the held-out test set — is necessary but entirely insufficient for any model intended to support regulatory submissions, market access negotiations, or clinical decision-making.
The Four Levels of Validation
A rigorous validation framework for claims-based predictive models has four levels, each addressing a different type of validity that the previous level cannot assess.
Internal validation confirms that the model has learned genuine patterns rather than overfitting the training data. Standard approaches — k-fold cross-validation, bootstrapping — are appropriate here. Internal validation tells you whether the model works on data from the same distribution as the training set. It tells you nothing about whether it will work on data from a different distribution.
Temporal validation tests the model on data from a later time period than the training set, using the same data source. This assesses whether the model’s learned patterns are stable over time — whether the relationships between features and outcomes in the training period still hold in the validation period. Claims data is particularly susceptible to temporal instability because coding practices, treatment guidelines, and healthcare system characteristics change over time in ways the training data doesn’t represent.
External validation tests the model on data from a different source — a different claims database, a different geographic market, or ideally a clinical dataset that provides outcome labels derived from chart review rather than administrative coding. External validation is the standard required for regulatory submissions and should be considered the minimum acceptable validation for market access applications. A model that hasn’t been externally validated has not been validated in any meaningful regulatory sense.
Clinical validation confirms that model predictions correspond to actual clinical outcomes in a prospective or quasi-prospective setting. This is the most demanding validation level and is required for any model that will directly influence clinical decision-making.
Performance Metrics That Matter
Accuracy is not an adequate performance metric for imbalanced healthcare outcome datasets — and most clinical outcomes in claims data are imbalanced. A model that predicts “no event” for every patient will achieve high accuracy on a dataset where 95% of patients don’t experience the outcome. That model is analytically worthless.
For patient stratification and clinical decision support, the relevant performance measures are discrimination (AUROC), calibration (Brier score, calibration curves), and net benefit analysis (decision curve analysis). Regulators and HTA bodies increasingly expect calibration evidence alongside discrimination evidence — a model that discriminates well but is poorly calibrated assigns systematically incorrect probabilities to patients, which undermines clinical utility regardless of AUROC.
For commercial forecasting, forecast accuracy metrics — mean absolute percentage error, prediction interval coverage — are more relevant than clinical discrimination metrics. The model needs to produce forecasts accurate enough to support resource allocation decisions.
Reporting Standards
The TRIPOD statement provides the reporting standard for prediction model development and validation studies. TRIPOD+AI extends this to machine learning models. FDA guidance on artificial intelligence and machine learning in software as a medical device establishes additional requirements for models used in clinical contexts. Any model intended for regulatory submission or market access support should be developed and reported against these standards from the outset — retrofitting documentation after model development is completed is substantially harder than building documentation into the development process.
Where Synthetic Data Helps and Where It Creates Risk
Synthetic data has genuine and growing applications in pharmaceutical predictive modelling. It also has limitations that are frequently understated in vendor conversations and overstated by advocates who have a commercial interest in its adoption. Understanding both clearly is necessary for making sound decisions about where synthetic data fits in a predictive modelling programme.
Where It Genuinely Helps
Training data augmentation for rare outcomes is the most analytically defensible application. When the outcome of interest is rare in the available real-world dataset — a safety event affecting one in a thousand patients, a disease progression pattern seen in fewer than fifty patients in the training cohort — GAN-based synthetic data generation with differential privacy guarantees can augment the training set to improve model performance on the minority class without exposing individual patient records to GDPR Article 9 constraints.
Algorithm development and testing under GDPR constraints is the second clear application. Developing and testing predictive model architectures on patient-level claims data triggers Article 9 obligations across Continental European markets. Synthetic data allows algorithm development to proceed without those constraints — the model architecture can be refined on synthetic data before being trained on the real dataset under appropriate data governance frameworks. This is covered in more detail in our post on aggregated and synthetic insurance data.
Scenario modelling for commercial forecasting is the third application — and the one with the fewest regulatory constraints. Generating synthetic patient trajectories consistent with assumed market conditions (competitive entry, guideline changes, policy shifts) extends the analytical reach of commercial forecasting models beyond the historical data available in the training set.
Where It Creates Risk
Using synthetic data as the primary training source for clinical prediction models is the risk that matters most. A model trained primarily on synthetic data has not been trained on clinical reality — it has been trained on a statistical approximation of an administrative data source. The synthetic generation process preserves statistical relationships present in the source claims data, but those relationships are themselves derived from billing patterns, not clinical ground truth. Neither FDA nor EMA currently accepts synthetic data as the primary evidence base for predictive model validation in regulatory submissions.
Calibration is the specific technical failure mode to watch for. Even where synthetic data produces well-discriminating models, calibration — the correspondence between predicted probabilities and observed event rates — is frequently compromised. Synthetic generation processes optimise for distributional similarity, not for the precise probability relationships that calibration requires. Models intended for clinical use, where calibration directly affects patient-level decision-making, should not rely on synthetic data for calibration validation.
The Advisory Perspective: Where Predictive Modelling Programmes Most Commonly Go Wrong
In the predictive modelling programmes we advise on across Continental European markets, the most consistent sources of failure are the ones that are hardest to detect from inside the programme. Data leakage that inflates internal validation metrics. Outcome label quality that was assumed rather than validated. Population representativeness gaps that only become visible when the model is applied in a market different from the one it was trained on.
What makes these failures particularly costly is that they’re often discovered late — after significant investment in model development, after internal stakeholders have formed expectations around model performance, sometimes after deployment. The independent review that would have caught them at the design stage wasn’t built into the programme timeline because it was seen as slowing down the work rather than protecting it.
The dataset evaluation checklist in our full guide at predictivemodeling.medddical.com provides the pre-training evaluation framework that catches these problems before they become expensive. And if you’re scoping a predictive modelling programme and want an independent assessment of your dataset requirements and validation framework before entering vendor conversations, contact us to discuss your specific evidence requirements. The decisions that determine whether a predictive modelling programme delivers clinical and commercial value are made at the beginning — not during model training or after deployment.
Sources & References
- Collins, G. S., et al. (2015). Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ, 350, g7594. https://www.bmj.com
- Moons, K. G. M., et al. (2019). PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Annals of Internal Medicine, 170(1), 51–58. https://www.acpjournals.org
- Wynants, L., et al. (2020). Prediction models for diagnosis and prognosis of Covid-19: systematic review and critical appraisal. BMJ, 369, m1328. https://www.bmj.com
- Vickers, A. J., & Elkin, E. B. (2006). Decision curve analysis: a novel method for evaluating prediction models. Medical Decision Making, 26(6), 565–574. https://journals.sagepub.com
- Jordon, J., et al. (2021). Synthetic data in machine learning for medicine and healthcare. Nature Biomedical Engineering, 5, 493–497. https://www.nature.com
- Chen, R. J., et al. (2023). Harnessing the power of synthetic data in healthcare: innovation, application, and privacy. npj Digital Medicine. https://www.nature.com
- U.S. Food and Drug Administration (2021). Artificial intelligence and machine learning (AI/ML)-based software as a medical device (SaMD) action plan. https://www.fda.gov
- U.S. Food and Drug Administration (2024). Real-world data: assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products. https://www.fda.gov
- ISPOR-ISPE Special Task Force. Good practices for real-world data studies of treatment and/or comparative effectiveness. https://www.ispor.org
- Hernán, M. A., & Robins, J. M. (2016). Using big data to emulate a target trial when a randomized trial is not available. American Journal of Epidemiology, 183(8), 758–764. https://academic.oup.com/aje
- Wilkinson, M. D., et al. (2016). The FAIR guiding principles for scientific data management and stewardship. Scientific Data, 3, 160018. https://www.nature.com
- Sáez, C., et al. (2023). Assessing the suitability of federated learning for deep learning-based medical image analysis. npj Digital Medicine. https://pubmed.ncbi.nlm.nih.gov